WO2000066141A3 - Pegylated interferon alfa-ccr5 antagonist combination hiv therapy - Google Patents

Pegylated interferon alfa-ccr5 antagonist combination hiv therapy Download PDF

Info

Publication number
WO2000066141A3
WO2000066141A3 PCT/US2000/011634 US0011634W WO0066141A3 WO 2000066141 A3 WO2000066141 A3 WO 2000066141A3 US 0011634 W US0011634 W US 0011634W WO 0066141 A3 WO0066141 A3 WO 0066141A3
Authority
WO
WIPO (PCT)
Prior art keywords
pegylated interferon
ccr5 antagonist
interferon alfa
hiv
antagonist combination
Prior art date
Application number
PCT/US2000/011634
Other languages
French (fr)
Other versions
WO2000066141A2 (en
Inventor
Mark A Laughlin
Original Assignee
Schering Corp
Mark A Laughlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00928604A priority Critical patent/EP1175224B1/en
Priority to NZ514519A priority patent/NZ514519A/en
Application filed by Schering Corp, Mark A Laughlin filed Critical Schering Corp
Priority to AU46815/00A priority patent/AU776541B2/en
Priority to JP2000615025A priority patent/JP2002543144A/en
Priority to AT00928604T priority patent/ATE289516T1/en
Priority to SI200030618T priority patent/SI1175224T1/en
Priority to MXPA01011116A priority patent/MXPA01011116A/en
Priority to DE60018273T priority patent/DE60018273T2/en
Priority to BR0010593-7A priority patent/BR0010593A/en
Priority to DK00928604T priority patent/DK1175224T3/en
Priority to CA002365900A priority patent/CA2365900A1/en
Priority to HU0202734A priority patent/HUP0202734A3/en
Publication of WO2000066141A2 publication Critical patent/WO2000066141A2/en
Publication of WO2000066141A3 publication Critical patent/WO2000066141A3/en
Priority to NO20015367A priority patent/NO328679B1/en
Priority to HK02100826.8A priority patent/HK1039278B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The use of a pegylated interferon-alfa and a CCR5 antagonist, further in association with at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with an anti-HIV-1 drug therapy, e.g., HAART, for preparation of a medicament for the treatment of HIV-1 infections as well as HIV-1 infections as well as HIV-1 and HCV co-infections in treatment-naive as well as treatment-experienced adult and pediatric patients are disclosed.
PCT/US2000/011634 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy WO2000066141A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
BR0010593-7A BR0010593A (en) 1999-05-04 2000-05-01 Combination therapy with pegylated ccr5-interferon alpha antagonist for hiv
DE60018273T DE60018273T2 (en) 1999-05-04 2000-05-01 PEGYLATED INTERFERON ALPHA IN COMBINATION WITH A CCR5 ANTAGONIST FOR AN HIV THERAPY
AU46815/00A AU776541B2 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
NZ514519A NZ514519A (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
AT00928604T ATE289516T1 (en) 1999-05-04 2000-05-01 PEGYLATED INTERFERON ALPHA IN COMBINATION WITH A CCR5 ANTAGONIST FOR HIV THERAPY
SI200030618T SI1175224T1 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
DK00928604T DK1175224T3 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa in combination with a CCR5 antagonist for HIV therapy
EP00928604A EP1175224B1 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
JP2000615025A JP2002543144A (en) 1999-05-04 2000-05-01 HIV therapy combined with PEGylated interferon αCCR5 antagonist
MXPA01011116A MXPA01011116A (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy.
CA002365900A CA2365900A1 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
HU0202734A HUP0202734A3 (en) 1999-05-04 2000-05-01 Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy
NO20015367A NO328679B1 (en) 1999-05-04 2001-11-02 Use of a pegylated interferon alfa and a CCR5 antagonist for the manufacture of a medicament for the treatment of HIV-1 infections.
HK02100826.8A HK1039278B (en) 1999-05-04 2002-02-02 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30489799A 1999-05-04 1999-05-04
US09/304,897 1999-05-04

Publications (2)

Publication Number Publication Date
WO2000066141A2 WO2000066141A2 (en) 2000-11-09
WO2000066141A3 true WO2000066141A3 (en) 2001-02-08

Family

ID=23178462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011634 WO2000066141A2 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy

Country Status (21)

Country Link
EP (1) EP1175224B1 (en)
JP (1) JP2002543144A (en)
CN (1) CN1349408A (en)
AR (1) AR023824A1 (en)
AT (1) ATE289516T1 (en)
AU (1) AU776541B2 (en)
BR (1) BR0010593A (en)
CA (1) CA2365900A1 (en)
DE (1) DE60018273T2 (en)
ES (1) ES2238277T3 (en)
HK (1) HK1039278B (en)
HU (1) HUP0202734A3 (en)
MX (1) MXPA01011116A (en)
MY (1) MY127670A (en)
NO (1) NO328679B1 (en)
NZ (1) NZ514519A (en)
PE (1) PE20010283A1 (en)
PT (1) PT1175224E (en)
TW (1) TWI289454B (en)
WO (1) WO2000066141A2 (en)
ZA (1) ZA200108870B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
CN101928284A (en) 2003-03-14 2010-12-29 小野药品工业株式会社 Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
WO2004092136A1 (en) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and use thereof
EP2364982A1 (en) 2003-04-18 2011-09-14 ONO Pharmaceutical Co., Ltd. Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
ES2294589T3 (en) 2004-04-29 2008-04-01 F. Hoffmann-La Roche Ag VARIATION OF THE NUCLEOSIDE SEQUENCE OF NS5A AS A MARKER.
US8143404B2 (en) 2004-09-13 2012-03-27 Ono Pharmaceutical Co., Ltd Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
PE20061012A1 (en) * 2005-02-23 2006-10-03 Schering Corp PIPERIDINYL PIPERAZINE DERIVATIVES AS INHIBITORS OF CHIOMYCIN RECEPTORS
JPWO2006129679A1 (en) 2005-05-31 2009-01-08 小野薬品工業株式会社 Spiropiperidine compounds and pharmaceutical uses thereof
PL1942108T3 (en) 2005-10-28 2014-03-31 Ono Pharmaceutical Co Compound containing basic group and use thereof
JP5217438B2 (en) 2005-11-18 2013-06-19 小野薬品工業株式会社 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF
US8003642B2 (en) 2006-03-10 2011-08-23 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JP6083818B2 (en) 2011-11-18 2017-02-22 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ Muscarinic M1 receptor agonist
US10272143B2 (en) 2014-01-08 2019-04-30 Immunovative Therapies Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042969A1 (en) * 1996-05-13 1997-11-20 F. Hoffmann-La Roche Ag USE OF IL-12 AND IFN-α FOR THE TREATMENT OF INFECTIOUS DISEASES
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998048840A1 (en) * 1997-04-29 1998-11-05 Schering Corporation Polyethylene glycol-interferon alpha conjugates for therapy of infection
WO1999017773A1 (en) * 1997-10-07 1999-04-15 Smithkline Beecham Corporation Compounds and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
EP0858343B1 (en) * 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042969A1 (en) * 1996-05-13 1997-11-20 F. Hoffmann-La Roche Ag USE OF IL-12 AND IFN-α FOR THE TREATMENT OF INFECTIOUS DISEASES
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998048840A1 (en) * 1997-04-29 1998-11-05 Schering Corporation Polyethylene glycol-interferon alpha conjugates for therapy of infection
WO1999017773A1 (en) * 1997-10-07 1999-04-15 Smithkline Beecham Corporation Compounds and methods

Also Published As

Publication number Publication date
BR0010593A (en) 2002-02-13
CN1349408A (en) 2002-05-15
JP2002543144A (en) 2002-12-17
TWI289454B (en) 2007-11-11
DE60018273D1 (en) 2005-03-31
MXPA01011116A (en) 2002-06-04
CA2365900A1 (en) 2000-11-09
HUP0202734A3 (en) 2003-11-28
ZA200108870B (en) 2003-03-26
MY127670A (en) 2006-12-29
ATE289516T1 (en) 2005-03-15
PE20010283A1 (en) 2001-03-16
NO20015367L (en) 2002-01-03
AU4681500A (en) 2000-11-17
AU776541B2 (en) 2004-09-16
PT1175224E (en) 2005-07-29
HK1039278A1 (en) 2002-04-19
NO328679B1 (en) 2010-04-26
EP1175224B1 (en) 2005-02-23
WO2000066141A2 (en) 2000-11-09
AR023824A1 (en) 2002-09-04
NO20015367D0 (en) 2001-11-02
DE60018273T2 (en) 2005-08-18
HUP0202734A2 (en) 2002-12-28
NZ514519A (en) 2003-07-25
ES2238277T3 (en) 2005-09-01
HK1039278B (en) 2005-06-30
EP1175224A2 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
WO2000066141A3 (en) Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
ES2251196T3 (en) USE OF PEG-IFN-ALFA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C.
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
DK0956861T3 (en) Combination therapy including ribavirin and interferon-alpha for patients with chronic hepatitis C infection who have not received antiviral therapy
BR0114636A (en) Pegylated interferon-alpha / ribavirin hcv combination therapy
EP0911033A3 (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
BR9712523A (en) New heterocyclyl-substituted pyrazole derivatives
AU1854695A (en) The use of interferon subtypes in the preparation of medicaments to treat viral infections
WO2002034284A3 (en) Methods of therapy for hiv infection
WO2000051631A3 (en) Pegylated alpha interferon for hiv therapy
WO2001066132A3 (en) Hiv immune adjuvant therapy
EP1023901A4 (en) Ameliorant for hepatitis c remedial effect and application thereof
HK1056838A1 (en) Use of agent for suppressing infection and proliferation of human immunodeficiency syndrome virus.
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
NZ514629A (en) PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment
WO2000043014A3 (en) Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
James Ribavirin approved for hepatitis C combination treatment
WO1999038524A3 (en) Therapeutic administration of low density lipoprotein receptor for viral infections and immune regulation
CA2130988A1 (en) Pharmaceutical Composition for Treatment of Sudden Deafness
AU8353601A (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
WO2000061175A3 (en) Use of pegylated interferon alpha in melanoma therapy
James Major study shows AZT monotherapy inferior
EP1731155A3 (en) Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections
AU2880495A (en) Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
TH45970A (en) HIV treatment with the combination of pegylates Interfiron Alpha - Anti-CCR5

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807116.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2365900

Country of ref document: CA

Ref document number: 2365900

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 514519

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000928604

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011116

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 615025

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 46815/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000928604

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 46815/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000928604

Country of ref document: EP